Cell and Gene Outsourcing

  1. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  2. Cell & Gene Therapy Development: Characterization Of Cellular Starting Material 6/21/2024

    Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

  3. Empowering Your Plasmid DNA Workflow 3/4/2025

    Unlock the full potential of your pDNA purification with advanced chromatography solutions and resins that tackle high viscosity and impurities to ensure superior quality and yield.

  4. Integrated Technologies And Glycosylation Tuning In Upstream Bioprocessing 7/1/2025

    Optimize mAb production with innovative cell culture media and feed designs. Explore integrated technologies, intensified fed-batch approaches, and methods to modulate glycosylation profiles in upstream bioprocessing.

  5. Accelerate Your AAV Journey To IND And Beyond 6/26/2025

    Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

  6. Viral Safety Of Biologics: What's Changing With The ICH Q5A Revision? 6/13/2022

    ICH Q5A is currently being revised to address recent scientific advancements. We'll discuss the expected changes and potential impact on viral safety strategies.

  7. Explore What's Next: Product Characterization 7/17/2019

    Newer, high-resolution analytical techniques help answer questions regarding product heterogeneity and drug functions, and help assess for product-related aggregates and impurities.

  8. Similar Enough Product Characterization To Support Process Changes And Biosimilar Development

    Characterization is essential to understand the impact following process changes and successful biosimilar development. Here, we provide best approaches for comparability studies.

  9. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma. 

  10. Virus Filtration In Continuous Processing: Novel Approaches For Optimal Performance 9/23/2024

    Watch to explore two novel approaches that have been developed to overcome the limitation of a filter's viral retention performance in continuous processes.